Neurocrine Biosciences Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Consensus Narrative from 26 Analysts
Future Focus On Crinecerfont And NBI-845 Will Diversify The Business
Key Takeaways Neurocrine's focus on pipeline development and strategic drug launches aims to drive revenue growth and business diversification. The company's share repurchase strategy could enhance earnings per share while leveraging perceived undervaluation.
View narrativeUS$163.69
FV
17.3% undervalued intrinsic discount16.39%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
Updated narrative